Cytokine Regulation of the Synthesis of Plasminogen Activator Inhibitor-2 by Human Vascular Endothelial Cells

Summary

Plasminogen activators are inhibited by plasminogen activator inhibitors-1 (PAI-1) and -2 (PAI-2). We describe the synthesis of PAI-2 by human vascular endothelial cells (EC) cultured from umbilical vein, saphenous vein and foreskin microvasculature in response to interleukin-1α (IL־1α) and tumour necrosis factor α (TNFα) and compare it with that of PAI-1. Both PAI-2 and PAI-1 were quantitated by ELIS As. PAI-2 was cell-associated while PAI-1 was secreted by EC. IL-lα and TNFα increased the synthesis of PAI-2 and PAI-1 by EC in a dose-dependent manner. IL-1α was a stronger stimulus for PAI-2 synthesis than TNFα, while both cytokines were equally effective for PAI-1. Northern blot analysis revealed similar changes in mRNA levels to those in antigen levels. PAI-2 synthesis by cytokine-stimulated EC may be important in thrombus formation and inflammation.

• References

• 1 Danø K, Andreasen PA, Gondahl-Hansen J, Kristensen P, Nielsen LS, Skriver J. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-265
• 2 Loskutoff DJ, Curriden SA. The fibrinolytic system of the vessel wall and its role in the control of thrombosis. Ann NY Acad Sci 1990; 598: 238-247
• 3 Thorsen S, Philips M, Selmer J, Lecander I, Astedt B. Kinetics of inhibition of tissue-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 1988; 175: 33-39
• 4 Kruithof EKO. Plasminogen activator inhibitors - A review. Enzyme 1988; 40: 113-121
• 5 Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 1989; 49: 2533-2553
• 6 Genton C, Kruithof EKO, Schleuning WD. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor-2 in high excess over urokinase type plasminogen activator in human 937-lymphoid cells. J Cell Biol 1987; 104: 705-712
• 7 Wohlwend A, Belin D, Vassalli JD. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med 1987; 165: 320-339
• 8 Kumar S, Baglioni C. Protection from tumour necrosis factor mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 20960-20964
• 9 Pytel B, Peppel K, Baglioni C. Plasminogen activator inhibitor type-2 is a major protein induced in human fibroblasts and SK-MEL-109 melanoma cells by tumour necrosis factor. J Cell Physiol 1990; 144: 416-422
• 10 Medcalf RL, Kruithof EKO, Schleuning WD. Plasminogen activator inhibitor 1 and 2 are tumour necrosis factor/cachectin responsive genes. J Exp Med 1988; 168: 751-759
• 11 Goeken NE, Staggs TS, Ballas ZK. Monocyte suppressor factor is plasminogen activator inhibitor, inhibition of membrane bound but not soluble IL-1. J Immunol 1989; 143: 603-608
• 12 Mantovani A, Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today 1989; 10: 370-375
• 13 Van Hinsbergh VWM, Van Den Berg EA, Fiers W, Dooijewaards G. Tumour necrosis factor induces the production of urokinase types plasminogen activator by human endothelial cells. Blood 1990; 75: 1991-1998
• 14 Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ. Cytokine activation of vascular endothelium. J Biol Chem 1988; 263: 5797-5803
• 15 Van Hinsbergh VWM, Kooistra T, van Den Berg EA, Princen HMG, Fiers W, Emeis JJ. Tumour necrosis factor increases the production of plasminogen activator inhibitor by human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-1473
• 16 Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. J Biol Chem 1989; 34: 20705-20713
• 17 Loskutoff DJ, Edington TS. Synthesis of fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci 1977; 74: 3903-3907
• 18 Gimbrone MA, Cotran R, Folkman JJ. Human vascular endothelial cells in culture. J Cell Biol 1974; 60: 673-684
• 19 Jackson CJ, Garbett PK, Nissen B, Schreiber L. Binding of human endothelium to Ulex europaeus 1-coated dynabeads: application to the isolation of microvascular endothelium. J Cell Sci 1990; 96: 257-263
• 20 Maciag T, Hoover GA, Stemerman MB, Wellnstein R. Factors which stimulate the growth of human umbilical vein endothelial cells in vitro. In: Biology of Endothelial Cells. Jaffe EA. (ed) Martinus Nijhoff Publ.; Dordrecht: 1984: 87-96
• 21 Jaffe EA, Hoyer LW, Nachman R. Synthesis of antihemophylic factor antigen by cultured human endothelial cells. J Clin Invest 1980; 52: 2757-2764
• 22 Stein O, Stein Y. Bovine aortic endothelial cells display macrophagelike properties towards acetylated ¹²⁵I-labelled low density lipoprotein. Biochem Biophys Acta 1980; 620: 631-635
• 23 Jaffe EA, Nachman RL, Becher CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756
• 24 Hamilton JA, Whitty GA, Last KA, Royston K, Burges DR. Interleukin-4 suppresses plasminogen activator inhibitor-2 formation in stimulated human monocytes. Blood. 1992 (in press)
• 25 Antalis TM, Clark MA, Barns T, Lehrbach PR, Devine PL, Schevozov G, Goss NH, Stephens RW, Tostoshev P. Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. Proc Natl Acad Sci USA 1985; 85: 955-959
• 26 Wojta J, Holzer M, Hufnagl P, Christ G, Hoover RL, Binder BR. Hyperthermia stimulates plasminogen activator inhibitor Type 1 expression in human umbilical vein endothelial cells in vitro. Am J Pathol 1991; 139: 911-919
• 27 Wagner OF, Binder BR. Purification of an active plasminogen activator inhibitor immunologically related to endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line. J Biol Chem 1986; 261: 14474-14481
• 28 Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribo-nuclease. Biochemistry 1979; 18: 5294-5299
• 29 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354
• 30 Niiya K, Takeuchi T, Kobayashi M, Miyoshi I, Hayashi T, Sakuagawa N. Dexamethasone and phorbol ester, but not cytokines increase the production of plasminogen activator inhibitor types-2 in the PL-21 human promyelocytic leukemia cell line. Thromb Haemostas 1991; 66: 232-238
• 31 Michel JB, Quertermous T. Modulation of mRNA levels for urinary-and tissue-type plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1. J Immunol 1989; 143: 890-895
• 32 Emeis J, Koositra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-1266
• 33 Schleef RR, Wagner NV, Loskutoff DJ. Detection of both type 1 and type 2 plasminogen activator inhibitor in human cells. J Cell Physiol 1988; 134: 269-274
• 34 Rånby M, Brändström A. Biological control of tissue plasminogen activator mediated fibrinolysis. Enzyme 1988; 40: 130-143
• 35 Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanims in atherosclerosis. Atherosclerosis 1989; 9: 567-578
• 36 Moore P. Immune mechanisms in the primary and secondary vasculitides. J Neurol Sci 1989; 93: 129-141
• 37 Anderson JR. The heart. In: Muirs Textbook of Pathology. 12.. Anderson JR. (ed) Edward Arnold (Publ); London: 1985
• 38 Goldblum SE, Henning B, Jay M, Kokichi Y, McClain CJ. Tumour necrosis factor β induced pulmonary endothelial injury. Infect Immun 1989; 57: 1218-1226
• 39 Schuger L, Varani J, Marks RM, Kunkel SL, Johnson KL, Ward PA. Cytotoxicity of tumour necrosis factor-β for human umbilical vein endothelial cells. Lab Invest 1989; 61: 62-68